Glucagon-like peptide 1 secretion

GLP-1 secretion" is not a molecule or receptor but rather a physiological process referring to the release of the hormone glucagon-like peptide 1 (GLP-1) from intestinal L-cells. GLP-1 is secreted in response to nutrient ingestion, especially glucose and fats, and plays a key role in enhancing glucose-dependent insulin secretion, inhibiting glucagon release, slowing gastric emptying, and reducing appetite[4][5][6]. The process of GLP-1 secretion involves complex neuroendocrine signaling pathways triggered by nutrients as well as neural and hormonal factors[3][4]. While drugs such as DPP-IV inhibitors or GLP‑1 receptor agonists are used therapeutically to modulate the effects of endogenous or exogenous GLP‑1 for conditions like type 2 diabetes and obesity[7][8], these drugs do not directly target "GLP‑1 secretion" itself but rather its downstream actions or degradation. Note: The correct molecular therapeutic target related to this process is typically the "Glucagon-like peptide 1 receptor (GLP‑1R)", not "GLP‑1 secretion". If you are seeking structured information for drug targeting purposes, use "Glucagon-like peptide 1 receptor" instead.

Other names

GLP-1 secretionGLP-1 releaseglucagon-like peptide 1 release